Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort.

Alessandro TomelleriCorrado CampochiaroSilvia SartorelliFrancesco BaldassiFederico FallancaMaria PicchioElena BaldisseraLorenzo Dagna

Published in: Modern rheumatology (2021)

In TAK, dose escalation is safe and allows to optimise infliximab durability in refractory patients. Younger patients seem to be more refractory to standard dosages.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes